Press Release
news head

September 6, 2018

Nucleix Announces Positive Results In Study Detecting Lung Cancer

read more >

Press Release
news head

July 31, 2018

CANCER SCREENING COMPANY NUCLEIX RAISES 2.5 MILLION EUROS

read more >

Press Release
news head

July 30, 2018

ISRAELI CANCER DETECTION CO NUCLEIX WINS €2.5M EU GRANT

read more >

Press Release
news head

July 26, 2018

CANCER DIAGNOSTICS FIRM NUCLEIX PLANS EUROPEAN MARKET EXPANSION

read more >

Press Release
news head

July 26, 2018

EUROPEAN STUDY GREEN-LIGHTS ISRAELI TEST FOR RECURRENCE OF BLADDER CANCER

read more >

Press Release
news head

July 24, 2018

NUCLEIX ANNOUNCES PUBLICATION OF NON-INVASIVE BLADDER CANCER RECURRENCE DETECTION STUDY SHOWING BEST-IN-CLASS PERFORMANCE

read more >

Article
news head

July 1, 2018

PERFORMANCE OF THE BLADDER EPICHECK™ METHYLATION TEST FOR PATIENTS UNDER SURVEILLANCE FOR NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS OF A MULTICENTER, PROSPECTIVE, BLINDED CLINICAL TRIAL

read more >

Article
news head

April 12, 2018

Bladder EpiCheck Multi-Center Study Results Were Presented During the European Association of Urology (EAU) Annual Meeting

Clinical results of multi-center study with five leading urology centers were accepted as a poster and presented during the EAU meeting in Copenhagen, Denmark. The EAU meeting is the largest urology meeting in Europe and 2nd largest in the world.

read more >

Press Release
news head

April 5, 2018

Leading European Bladder Cancer Experts: The Bladder EpiCheck Urine Test Can Reduce Invasive Procedures

read more >

Article
news head

November 20, 2017

Nucleix Exhibited Bladder EpiCheck at the Annual Meeting of the European Multidisciplinary Meeting on Urological Cancers (EMUC)

Nucleix exhibited Bladder EpiCheck, best-in-class bladder cancer monitoring test, during the European Multidisciplinary Meeting on Urological Cancers (EMUC). The EMUC meeting one of Europe’s well-attended international conferences for multidisciplinary specialists with expertise in urological malignancies. During the meeting, Nucleix met

read more >